Take a look around.
Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)
Bayer today presented subgroup analysis data of patients with non-small cell lung cancer with neurotrophic receptor tyrosine kinase (NTRK) gene fusion treated with Vitrakvi® (larotrectinib).1...Learn more
Bayer welcomes science-based discussion with regulators, researchers and the public: More than 100 Bayer-owned glyphosate safety study reports accessible as Monsanto integration continues
Bayer welcomes a science-based discussion with regulators around the globe, the international research community, as well as with consumers on the safety profile of glyphosate. To that end, all...Learn more
Explore Our Divisions
In line with our mission “Bayer: Science for A Better Life,” we aim to improve people’s quality of life.